KEGG   DISEASE: Multiple sclerosis
Entry
H01490                      Disease                                
Name
Multiple sclerosis
Description
Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by inflammation, demyelination and axonal loss. This disease typically strikes young adults, especially women. There are four types of MS according to their relapsing or progressive pattern that include relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). In most patients, the disease has a relapsing-remitting course during the first years. Within 10 years, approximately 50% of patients progress to SPMS. The aetiology of MS is not well understood, but it is likely multifactorial, combining both genetic and environmental factors. Recently, the literature on the risk factors for MS has grown substantially. They indicate that a combination of a genetic predisposition, exposure to Epstein-Barr virus, cigarette smoking, and reduced sunlight exposure/vitamin D levels is involved. Authorized first-line treatments are considered equally effective, and include interferon beta and glatiramer acetate. They are primarily directed against inflammation, and might fail to adequately control disease activity in some patients. In that case, it has been recommended to switch these patients early to a therapy of higher efficacy. Currently, 13 different drugs with ten different active components are licensed in the European Union (EU) and the United States (US) for the treatment of MS.
Category
Immune system disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 08 Diseases of the nervous system
  Multiple sclerosis or other white matter disorders
   8A40  Multiple sclerosis
    H01490  Multiple sclerosis
Pathway-based classification of diseases [BR:br08402]
 Signal transduction
  nt06516  TNF signaling
   H01490  Multiple sclerosis
 Cellular process
  nt06527  Necroptosis
   H01490  Multiple sclerosis
 Immune system
  nt06537  TCR/BCR signaling
   H01490  Multiple sclerosis
Pathway
hsa04658 Th1 and Th2 cell differentiation   
hsa04659 Th17 cell differentiation   
hsa04612 Antigen processing and presentation   
hsa04217 Necroptosis   
hsa04660 T cell receptor signaling pathway   
Network
nt06516 TNF signaling
nt06527 Necroptosis
nt06537 TCR/BCR signaling
Gene
(MS) PDCD1 [HSA:5133] [KO:K06744]
(MS) HLA-DRB1 [HSA:3123] [KO:K06752]
(MS) HLA-DQB1 [HSA:3119] [KO:K06752]
(MS5) TNFRSF1A [HSA:7132] [KO:K03158]
Pathogen
Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
Drug
Triamcinolone acetonide [DR:D00983]
Dexamethasone [DR:D00292]
Hydrocortisone [DR:D00088]
Hydrocortisone sodium succinate [DR:D00978]
Prednisolone sodium phosphate [DR:D00981]
Prednisone [DR:D00473]
Methylprednisolone [DR:D00407]
Methylprednisolone sodium succinate [DR:D00751]
Methylprednisolone acetate [DR:D00979]
Corticotropin [DR:D00146]
Cladribine [DR:D01370]
Mitoxantrone hydrochloride [DR:D02166]
Ofatumumab [DR:D09314]
Interferon beta-1a [DR:D04554]
Interferon beta-1b [DR:D00746]
Peginterferon beta-1a [DR:D10483]
Glatiramer acetate [DR:D04318]
Daclizumab [DR:D03639]
Fingolimod hydrochloride [DR:D04187]
Ozanimod hydrochloride [DR:D10967]
Siponimod fumarate [DR:D11072]
Ponesimod [DR:D11215]
Natalizumab [DR:D06886]
Alemtuzumab [DR:D02802]
Ocrelizumab [DR:D05218]
Ublituximab [DR:D11243]
Teriflunomide [DR:D10172]
Dimethyl fumarate [DR:D03846]
Diroximel fumarate [DR:D11154]
Baclofen [DR:D00241]
Dantrolene sodium [DR:D02274]
Dalfampridine [DR:D04127]
Monomethyl fumarate [DR:D11492]
Fingolimod lauryl sulfate [DR:D12549]
Other DBs
ICD-11: 8A40
ICD-10: G35
MeSH: D009103
OMIM: 126200 614810
Reference
  Authors
Milo R, Miller A
  Title
Revised diagnostic criteria of multiple sclerosis.
  Journal
Autoimmun Rev 13:518-24 (2014)
DOI:10.1016/j.autrev.2014.01.012
Reference
  Authors
McKay KA, Kwan V, Duggan T, Tremlett H
  Title
Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.
  Journal
Biomed Res Int 2015:817238 (2015)
DOI:10.1155/2015/817238
Reference
  Authors
Goris A, Pauwels I, Dubois B
  Title
Progress in multiple sclerosis genetics.
  Journal
Curr Genomics 13:646-63 (2012)
DOI:10.2174/138920212803759695
Reference
PMID:15912506 (PDCD1)
  Authors
Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Maurer M, Wiendl H
  Title
A PD-1 polymorphism is associated with disease progression in multiple sclerosis.
  Journal
Ann Neurol 58:50-7 (2005)
DOI:10.1002/ana.20514
Reference
PMID:14669136 (HLA-DRB1 HLA-DQB1)
  Authors
Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL
  Title
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.
  Journal
Am J Hum Genet 74:160-7 (2004)
DOI:10.1086/380997
Reference
PMID:22801493 (TNFRSF1A)
  Authors
Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Promel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L
  Title
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
  Journal
Nature 488:508-511 (2012)
DOI:10.1038/nature11307
LinkDB

» Japanese version

DBGET integrated database retrieval system